The DEA's recent review disregards scientific evidence on cannabis' medicinal benefits, asserting it has high abuse potential with no accepted medical use, despite contrary peer-reviewed studies.
The classification of cannabis as a Schedule I substance has historically hindered research on its medical applications. Effective studies on pain management and multiple conditions remain overlooked.
This review process has been biased, consistently omitting peer-reviewed research that supports cannabis' therapeutic values and maintaining the agency's long-held restrictive views.
The DEA's actions signify a troubling commitment to outdated drug war narratives, obstructing progress in medical research and reform based on modern scientific understanding.
Collection
[
|
...
]